Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups

Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups

Abstract Background Immunotherapy is now standard of care for multiple myeloma (MM), where the most common targets are B cell maturation antigen, CD38, and G protein-coupled receptor class C group 5 member D (GPRC5D). However, additional novel targets are needed to counter tumor heterogeneity, there...

Full description

Saved in:
Bibliographic Details
Main Authors: Enze Liu, Oumaima Jaouadi, Riya Sharma, Nathan Becker, Travis S. Johnson, Parvathi Sudha, Vivek S. Chopra, Faiza Zafar, Habib Hamidi, Charlotte Pawlyn, Attaya Suvannasankha, Rafat Abonour, Brian A. Walker
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Genome Medicine
Online Access:https://doi.org/10.1186/s13073-025-01503-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13073-025-01503-y

Similar Items